| 51.5 -3.57 (-6.48%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 66.73 | 1-year : | 77.95 |
| Resists | First : | 57.13 | Second : | 66.73 |
| Pivot price | 41.68  |
|||
| Supports | First : | 40.29 |
Second : | 29.87 |
| MAs | MA(5) : | 52.08 |
MA(20) : | 39.37 |
| MA(100) : | 29.37 |
MA(250) : | 19.38 |
|
| MACD | MACD : | 5.4 |
Signal : | 3.6 |
| %K %D | K(14,3) : | 86.7 |
D(3) : | 85.8  |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 57.13 | Low : | 3.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NBTX ] has closed below upper band by 20.7%. Bollinger Bands are 321.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 54.01 - 54.3 | 54.3 - 54.54 |
| Low: | 48.96 - 49.26 | 49.26 - 49.52 |
| Close: | 50.99 - 51.52 | 51.52 - 51.97 |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Thu, 14 May 2026
Nanobiotix SA - Depositary receipt (NBTX) price target increased by 26.60% to 34.52 - MSN
Mon, 04 May 2026
Head and neck cancer trial skips interim check, moves readout up - Stock Titan
Mon, 04 May 2026
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study - ChartMill
Mon, 04 May 2026
Nanobiotix (NBTX) gets FDA nod for faster NANORAY-312 Phase 3 readout - Stock Titan
Fri, 01 May 2026
UBS raises Nanobiotix stock price target to $30 on reduced risk - Investing.com
Fri, 03 Apr 2026
Nanobiotix S.A. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:NBTX) 2026-04-03 - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 11.7 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 15 (K) |
| EPS | -0.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.04 |
| Profit Margin | -73.6 % |
| Operating Margin | -196.5 % |
| Return on Assets (ttm) | -10.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.67 |
| Sales Per Share | 0.67 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -87.29 |
| PEG Ratio | 0 |
| Price to Book value | -25.25 |
| Price to Sales | 76.64 |
| Price to Cash Flow | -74.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|